W. Michael Korn, MD

Philipps University of Marburg, Germany, Continuing Education, 1981 - 1984, Medicine
Heinrich-Heine University of Düsseldorf, Germany, Approbation as Physician, 1984 - 1988, Medicine
Philipps University of Marburg, Germany, Medical Doctorate, 1993
University of Bern, Switzerland, Internship, 1997, Medicine

• 1988-1992
  Physician in Training, Ev. Krankenhaus Dinslaken, Germany
• 1992-1996
  Physician in Training, West German Cancer Center, University of Essen, Medical School, Essen, Germany
• 1996
  Certified Internist, West German Cancer Center, University of Essen, Medical School, Essen, Germany
• 1996
  Interim Head, Laboratory of Tumor Cytogenetics, West German Cancer Center, University of Essen, Medical School, Essen Germany
• 1996-1997
  Postdoctoral Fellow, Cancer Genetics Program, UCSF Cancer Center, University of California San Francisco, California
• 1997
  Postdoctoral Fellow, Cancer Research Institute, UCSF Cancer Center, University of California San Francisco
• 1997-1999
  Assistant Research Biochemist, Cancer Research Institute, UCSF Cancer Center, University of California San Francisco
• 1999-2004
  Assistant Adjunct Professor of Medicine, Division of Gastroenterology, University of California San Francisco
• 2004-2006
  Assistant Adjunct Professor of Medicine, Divisions of Gastroenterology and Medical Oncology, University of California San Francisco
• 2006-present
  Associate Professor of Medicine in Residence, Divisions of Gastroenterology and Medical Oncology, University of California San Francisco
• 2008-present
  Co-Director, Center of Molecular Oncology, University of California San Francisco

• 1996
  Mildred-Scheel Research Fellowship, Mildred Scheel Stiftung e.V., Germany
• 2001
  Hellman Family Award
• 2008
  Cancer League Award
• 2009
  Helen Diller Family Quality Award

• Anders, M., Christian, C., McMahon, M., McCormick, F, and Korn, W.M., Inhibition of the Raf-MEK-ERK pathway upregulates expression of the Coxsackievirus and Adenovirus Receptor in cancer cells. Cancer Res 2003, 63: 2088-95
• Lacher, M., Anders, M., Oft, M., Balmain, A., Korn, W.M., TGFβ receptor inhibition enhances adenoviral infectivity of carcinoma cells via up-regulation of CAR consequent to mesenchymal-epithelial-transition. Cancer Res. 2006; 66:1648-57
• Mirzoeva, O.K., Das, D., Heiser, L.M., Bhattacharya, S., Siwak, D., Gendelman, R., Bayani, N., Wang, N.J., Neve, R.M., Parvin, P., Knight, Z., Feiler, H.S., Gascard, P., Spellman, P.T., Shokat, K.M., Wyrobek, A., Bissell, M.J., McCormick, F., Kuo, W.-L., Mills, G.M., Gray, J.W., Korn, W.M., Basal-subtype and MEK-PI3K feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. Cancer Research, 2009; 69: 565-72
• Chien, A.J., Illi, J.A. Ko, A.H., Korn, W.M., Fong, L. Chen, L.M., Kashani-Sabet, M., Ryan, C.J., Rosenberg, J.E., Dubey, S., Small, E.J., Jahan, T.M., Hylton, N.M., Yeh, B.M., Huang, Y., Koch, K.M., Moasser, M.M., A phase 1 study of a 2 day lapatinib chemosensitization pulse preceding nanoparticle albumin-bound paclitaxel for advanced solid malignancies. Clinical Cancer Research, 2009; 15:5569-75
• Ko, A.H., Venook, A.P., Bergsland, E.K., Kelley, R.K., Korn, W.M., Dito, E., Schillinger, B. Scott, Hwang, J., Tempero, M.A., A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer. Cancer Chemotherapy and Pharmacology, 2010; 66:1051-1057
• Bagheri, N, Shiina, M., Lauffenburger, D., Korn, W.M., Dynamic mathematical modeling of optimized combinations of oncolytic adenoviruses and MEK for the treatment of solid tumors. PLOS Computational Biology, Feb;7(2):e1001085 [Epub ahead of print].
• Mirzoeva, O., Knight, Z., Debnath, J., Shokat, K., Korn, W.M., Inhibition of autophagy promotes apoptotic cell death in response to inhibition of the PI3 kinase - mTOR pathway in pancreatic adenocarcinoma cells. J. Molecular Medicine, 10.1007/s00109-011-0774-y [Epub ahead of print].
• Additional recent publications of importance to the field:
• Korn, W.M., Yasutake, T., Kuo, W.-L., Warren, R.S., Collins, C., Tomita, M., Gray, J., Waldman, F.M., Chromosome 20q gains and other genomic copy number changes in metastatic colorectal cancer analyzed by comparative genomic hybridization and fluorescence in situ hybridization. Genes Chromosom. Cancer 1999, 25: 82-90
• Ries, S.J., Brandts, C.H., Chung, A.S., Biederer, C.H., Hann, B.C., Lipner, E.M. McCormick, F., Korn, W.M., Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant dl1520 (ONYX-015). Nat. Med., 2000, 6: 1128-33
• Yount, G.L., Afshar, G., Ries, S., Korn, M., Shalev, N., Aldape, K.D., McCormick, F., Haas-Kogan, D.A., Transcriptional Activation of TRADD mediates p53-independent radiation-induced apoptosis in glioma cells. Oncogene 2001, 20, 2826-35
• Anders, M., Hansen, R., Ding, R.-X. Rauen, K.A., Bissell, M.J., Korn, W.M., Disruption of three-dimensional tissue integrity facilitates adenovirus infection by deregulating the Coxsackievirus and Adenovirus Receptor. PNAS, 2003, 100:1943-48
• Korn, W.M., Macal, M., Christian, C., Ding, R.-X., Rauen, K.A., Warren, R.S., and Ferrell, L., Expression of the Coxsackievirus and Adenovirus Receptor in gastrointestinal tumors correlates with tumor differentiation. Cancer Gene Therapy, 2006; 13:792-7
• Au, T., Thorne, S., Korn, W.M., Sze, D., Kirn, D., and Reid, T.R. Minimal hepatic toxicity pf ONYX-015: spatial restriction of CAR receptor in normal liver. Cancer Gene Therapy, 2007, 14: 139-150
• Shiina, M., Lacher, M., Christian, C., Korn, W.M., RNAi-mediated knock-down of p21WAF1 enhances anti-tumor activity of oncolytic adenoviruses. Cancer Gene Therapy, 2009; 16:810-9